Rebounding with Strength: AI Innovation, Health Care Tools and Sports Legacy Drive MDCE’s Expansion
MESA, AZ / ACCESS Newswire / August 22, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) is entering a major rebound phase in 2025, marked by rapid growth and innovation across its subsidiaries. The company reported that Q2 revenue surged by over 2,500% year-over-year, with momentum continuing into Q3 where performance is on pace to exceed those results.
At the core of MDCE’s resurgence is its proprietary AI imaging system, now patent-pending (U.S. Provisional Patent Application No. 63/854,935). This groundbreaking technology enhances medical diagnostic imaging while also powering AI-driven authentication for high-value collectibles, showcasing the company’s ability to bridge healthcare and culture through applied innovation.
MDCE’s Three Growth Engines:
Medical Care Technologies – Developing smartphone-based AI diagnostic tools for real-time healthcare monitoring and early disease detection.
Real Game Used – Delivering AI-powered authentication and photo-match verification for sports and entertainment memorabilia.
Infinite Auctions – A premier auction house currently featuring “The Grail Collection”, an unprecedented offering of historic memorabilia including iconic game-worn items from Michael Jordan and other legends.
“2025 represents a true turning point for MDCE,” said Marshall Perkins III, CEO of Medical Care Technologies Inc.“With our patent-pending technology and the explosive growth of our subsidiaries, we’re scaling aggressively in healthcare and collectibles while creating sustainable long-term value for shareholders.”
For more information, visit www.mdcestock.com, www.infiniteauctions.com, www.realgameused.com.
Safe Harbor Statement
This release may contain forward-looking statements subject to risks and uncertainties. Actual results may differ materially, and the Company assumes no obligation to update these statements.
SOURCE: Medical Care Technologies Inc. (OTC PINK:MDCE)
View the original press release on ACCESS Newswire
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…